We are currently working to resolve technical issues preventing us from processing applications, bookings or payment for membership. Please email Membership on membership@rheumatology.org.uk with any queries.
COVID-19
Jobs
eLearning
Journals
Rheumatology
Rheumatology Advances in Practice
Musculoskeletal Care
Login
My BSR
Search
About
Who we are
Our People
Our Trustees
Committees
Devolved Nations
Regions
Special interest groups
Vision, mission & values
Careers in rheumatology
Rheumatology Taster Days
Specialty Certificate Examination
Versus Arthritis handbook
Working with BSR
Jobs at BSR
News & Policy
Events & Learning
Conferences
Annual Conference
Courses
Core Skills in Rheumatology
Quality Improvement
Rheumatology for Specialist Nurses
Foot and ankle
Developmentally appropriate care for young people
Ultrasound for Rheumatology Practice
Webinars
Awards
Bursaries
Education bursary
Fellowships
Practice & Quality
Audits
NEIAA
Lupus
Guidelines
Paediatric and adolescent guidance
Commissioning
Frameworks
COVID-19 guidance
Registers
Rheumatoid Arthritis
Ankylosing Spondylitis
Juvenile Idiopathic Arthritis
Psoriatic Arthritis
Published papers
Requesting registers data
Policy
Research
Best Practice Awards
ePROMs
Quality Review
Membership
Join
Benefits
FAQs
Mentoring
Search
My BSR
Login
About
Who we are
Our People
Our Trustees
Committees
Devolved Nations
Regions
Special interest groups
Vision, mission & values
Careers in rheumatology
Rheumatology Taster Days
Specialty Certificate Examination
Versus Arthritis handbook
Working with BSR
Jobs at BSR
News & Policy
Events & Learning
Conferences
Annual Conference
Courses
Core Skills in Rheumatology
Quality Improvement
Rheumatology for Specialist Nurses
Foot and ankle
Developmentally appropriate care for young people
Ultrasound for Rheumatology Practice
Webinars
Awards
Bursaries
Education bursary
Fellowships
Practice & Quality
Audits
NEIAA
Lupus
Guidelines
Paediatric and adolescent guidance
Commissioning
Frameworks
COVID-19 guidance
Registers
Rheumatoid Arthritis
Ankylosing Spondylitis
Juvenile Idiopathic Arthritis
Psoriatic Arthritis
Published papers
Requesting registers data
Policy
Research
Best Practice Awards
ePROMs
Quality Review
Membership
Join
Benefits
FAQs
Mentoring
COVID-19
Jobs
eLearning
Journals
Rheumatology
Rheumatology Advances in Practice
Musculoskeletal Care
Commissioning
Overview
Guidance and advice for clinicians on engaging with CCGs and specialist commissioners. Information on this page is currently England-specific.
With more than 200 distinct conditions covered within rheumatology, designing and commissioning rheumatology services presents a significant challenge.
Service design covers a broad range of concerns that professionals may encounter when reviewing the commissioning of rheumatology services within their trust.
The majority of rheumatic musculoskeletal diseases (RMDs) are long-term conditions that require regular, planned and strategic care by rheumatology specialist multidisciplinary teams.
People who may have RMDs initially require prompt assessment, accurate diagnosis and early medical management to reduce symptoms and morbidity and reduce the risk of long-term disability – as preventive medical management is key.
Resources on this page cover areas including access to care, delivery of services, rare conditions, working with primary care, workforce planning, and specialised commissioning. Specific queries on commissioning not covered by the general advice on this page should be directed to our
policy team
.
FAQs
What guidance is there for commissioning high-cost drugs?
There are a number of NHSE-approved clinical commissioning policies in place for the routine commissioning of high cost drugs.
Each policy has specific criteria which include requirements for the patient to be managed at, or in conjunction with, a specialised rheumatology centre and, where indicated in each policy, a requirement for enrolment (subject to consent) in the appropriate registry:
Teriparatide for osteoporosis in men
(adults)
Rituximab in ANCA-associated vasculitis
Sildenafil and bosentan for the treatment of digital ulceration in systemic sclerosis
Rituximab for the treatment of dermatomyositis and polymyositis
(adults)
Tocilizumab for Takayasu arteritis
(adults)
Rituximab for immunoglobulin G4-related disease
Anakinra and tocilizumab for adult-onset Stills Disease
Has NICE published any guidance on the use of biologics?
In June 2016, NICE published guidance for the use of
belimumab for treating active auto antibody-positive SLE
. It has taken extensive negotiation and discussion to reach this position, which the CRG has been very closely involved with.
It is a significant success for patient care that rheumatology now has access to both biologic drugs. Please note the pathway which must be followed when considering the use of either belimumab or rituximab in SLE.
In April 2018, NICE published guidance for the use of
tocilizumab in patients with refractory or relapsing giant cell arteritis (GCA)
.
What's the role of regional and specialty teams?
Regional networks and regional multidisciplinary/specialty team meetings are key to facilitating the delivery of specialised services for rheumatology patients, including the implementation of commissioning policies.
The CRG has worked hard over the last six years to try and create the commissioning opportunities and levers to enable this network development.
Is there any guidance on how to complete the specialised rheumatology quality dashboard?
The completion of the quarterly specialised rheumatology quality dashboard is mandatory for specialised centres. It provides real-time data for providers and commissioners regarding waiting times for new patient appointments, use of high-cost drugs and enrolment of patients on the specified registries in the clinical commissioning policies and NICE guidance.
If your centre requires advice about how to register to do this, please
get in touch
.
The work of NHS England’s specialised services is becoming more focused on patient outcomes, value for money and ‘getting it right first time’. The group will continue to develop commissioning policies for the use of drugs in patient cohorts that are included within the specialised rheumatology service specification, which is also currently being revised.
The need for policies is informed from multiple sources including horizon scanning and individual funding requests (IFR). If you have any suggestions for new policies that you think are required, please tell us.
Service design: an overview
Read more
Top service design tips
Read more